EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

Millions of people around the world believe that we are not the only creatures living in this universe and UFOs and alien ...

Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received a GMP ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

“University Hospitals, Portage Medical Center ... Throughout the year, Portage County EMA will also be running test scenarios ...

NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Ahead of this weekend’s MTV EMAs, Paramount Global, has revealed that it’s pledging cash towards a state-of-the-art ...

The Bulloch County Sheriff’s Office is asking the public to allow extra time on their commutes Thursday morning after ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

"The [EMA's] Medicines-For-All procedure will facilitate ... science and PrEP service delivery at Jhpiego (a Johns Hopkins University affiliate) in Kenya. The study, which examines the choices ...

Four seats on the Desert Healthcare District and Foundation Board of Directors are up for grabs on Nov. 5. Coachella Valley voters will also decide the fate of Measure AA, which will approve or reject ...